# AMG 386 and Abiraterone for Advanced Prostate Cancer

> **NCT01553188** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 36 (actual)

## Conditions studied

- Prostatic Neoplasms
- Prostate Cancer
- Neoplasm, Prostate
- Neoplasm,Prostatic

## Interventions

- **DRUG:** AMG 386
- **DRUG:** Abiraterone
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT01553188
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-08
- **Primary completion:** 2017-04-20
- **Final completion:** 2018-07-01
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2019-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01553188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01553188, "AMG 386 and Abiraterone for Advanced Prostate Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01553188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*